TY - JOUR
T1 - DNA damage and expression of checkpoint genes p21WAF1/CIP1 and 14-3-3 σ in taurine-deficient cardiomyocytes
AU - Golubnitschaja, Olga
AU - Moenkemann, Heike
AU - Kim, Kerstin
AU - Mozaffari, Mahmood S.
PY - 2003/8/1
Y1 - 2003/8/1
N2 - Objective: Taurine depletion is associated with development of cardiomyopathy. Further, oxidative stress is advanced as a critical factor mediating the effect of taurine deficiency on target organs. However, the molecular mechanism(s) linking taurine deficiency with the development of cardiomyopathy remains elusive. Since transition between apoptotic degeneration and cell proliferation in stress conditions is regulated at cell cycle checkpoints, we determined the expression of two such genes, namely p21WAF1/CIP1 and 14-3-3 σ as well as p53 that are responsible for oxidative stress and DNA damage. We also carried out quantitative determination of DNA damage. Methods: Cardiomyocytes from β-alanine-induced taurine-depleted (TD) rats were used for this investigation. Single- and double-stranded DNA damage was quantified using comet assay analysis. Western blot and two-dimensional polyacrylamide gel electrophoresis with immunoblotting analysis were applied for protein analysis. Results: Comet assay analysis indicated that the extent of double-stranded DNA damage was greater in TD than in control cardiomyocytes. Whereas only traces of both p53 and p21WAF1/CIP1 and no detectable expression of 14-3-3 σ were found in cardiomyocytes of control animals, the TD cardiomyocytes expressed all three genes. Conclusions: DNA damage and the consequent up-regulation of checkpoint proteins observed in TD cardiomyocytes indicate the involvement of cell cycle control mechanisms in the effect of taurine deficiency on cardiomyocytes. Single- and double-stranded DNA damage and the consequent arrest of cell proliferation in both G1 and G2 phases of the cell cycle induced by checkpoint proteins may trigger the cardiomyopathy that is associated with taurine deficiency.
AB - Objective: Taurine depletion is associated with development of cardiomyopathy. Further, oxidative stress is advanced as a critical factor mediating the effect of taurine deficiency on target organs. However, the molecular mechanism(s) linking taurine deficiency with the development of cardiomyopathy remains elusive. Since transition between apoptotic degeneration and cell proliferation in stress conditions is regulated at cell cycle checkpoints, we determined the expression of two such genes, namely p21WAF1/CIP1 and 14-3-3 σ as well as p53 that are responsible for oxidative stress and DNA damage. We also carried out quantitative determination of DNA damage. Methods: Cardiomyocytes from β-alanine-induced taurine-depleted (TD) rats were used for this investigation. Single- and double-stranded DNA damage was quantified using comet assay analysis. Western blot and two-dimensional polyacrylamide gel electrophoresis with immunoblotting analysis were applied for protein analysis. Results: Comet assay analysis indicated that the extent of double-stranded DNA damage was greater in TD than in control cardiomyocytes. Whereas only traces of both p53 and p21WAF1/CIP1 and no detectable expression of 14-3-3 σ were found in cardiomyocytes of control animals, the TD cardiomyocytes expressed all three genes. Conclusions: DNA damage and the consequent up-regulation of checkpoint proteins observed in TD cardiomyocytes indicate the involvement of cell cycle control mechanisms in the effect of taurine deficiency on cardiomyocytes. Single- and double-stranded DNA damage and the consequent arrest of cell proliferation in both G1 and G2 phases of the cell cycle induced by checkpoint proteins may trigger the cardiomyopathy that is associated with taurine deficiency.
KW - Cardiomyocytes ex vivo
KW - Checkpoint proteins
KW - Comet assay
KW - DNA damage
KW - Gene expression
KW - Taurine depletion
UR - http://www.scopus.com/inward/record.url?scp=0042196178&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0042196178&partnerID=8YFLogxK
U2 - 10.1016/S0006-2952(03)00285-5
DO - 10.1016/S0006-2952(03)00285-5
M3 - Article
C2 - 12907251
AN - SCOPUS:0042196178
SN - 0006-2952
VL - 66
SP - 511
EP - 517
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 3
ER -